Parmar, A.;                     Dai, W.F.;                     Dionne, F.;                     Geirnaert, M.;                     Denburg, A.;                     Ahuja, T.;                     Beca, J.;                     Bouchard, S.;                     Chambers, C.;                     Hunt, M.J.;     
    et al.    Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Curr. Oncol. 2023, 30, 3776-3786.
    https://doi.org/10.3390/curroncol30040286
    AMA Style
    
                                Parmar A,                                 Dai WF,                                 Dionne F,                                 Geirnaert M,                                 Denburg A,                                 Ahuja T,                                 Beca J,                                 Bouchard S,                                 Chambers C,                                 Hunt MJ,         
        et al.        Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Current Oncology. 2023; 30(4):3776-3786.
        https://doi.org/10.3390/curroncol30040286
    
    Chicago/Turabian Style
    
                                Parmar, Ambica,                                 Wei Fang Dai,                                 Francois Dionne,                                 Marc Geirnaert,                                 Avram Denburg,                                 Tarry Ahuja,                                 Jaclyn Beca,                                 Sylvie Bouchard,                                 Carole Chambers,                                 Melissa J. Hunt,         
         and et al.        2023. "Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration" Current Oncology 30, no. 4: 3776-3786.
        https://doi.org/10.3390/curroncol30040286
    
    APA Style
    
                                Parmar, A.,                                 Dai, W. F.,                                 Dionne, F.,                                 Geirnaert, M.,                                 Denburg, A.,                                 Ahuja, T.,                                 Beca, J.,                                 Bouchard, S.,                                 Chambers, C.,                                 Hunt, M. J.,                                 Husereau, D.,                                 Lungu, E.,                                 McDonald, V.,                                 Mercer, R. E.,                                 Mitera, G.,                                 Muñoz, C.,                                 Naipaul, R.,                                 Peacock, S.,                                 Potashnik, T.,         
                                            ... Chan, K. K. W.        
        (2023). Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Current Oncology, 30(4), 3776-3786.
        https://doi.org/10.3390/curroncol30040286